In our view, on the basis of evidence for growing demand for Catalyst and OssDsign's strong ability to continuously add further hospital approvals, we see reasons to believe OssDsign's strong sales momentum will remain. Scalability should improve based on the closure of the Cranial PSI business line, we believe, provided sales commissions fall as a percent of sales. According to management, gross margins will rise towards 90% in 2024, which should provide support.

SEB Research

This research has been commissioned by the company. Only for professional investors resident in EEA member states. Reports may not be distributed to the US or other jurisdictions where to do so would be unlawful. Please see the disclaimer tab for any details of investment banking services recently provided by SEB that could be considered relevant to the subject matter of this research.